BCI-215
Modify Date: 2024-01-08 20:07:19
BCI-215 structure
|
Common Name | BCI-215 | ||
|---|---|---|---|---|
| CAS Number | 1245792-67-9 | Molecular Weight | 396.328 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H22BrNO | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BCI-215BCI-215 (BCI215) is a potent, tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor; restores defective MAPK activity caused by overexpression of DUSP1 and DUSP6 in mammalian cells; inhibits cell motility, causes apoptosis but not primary necrosis, and sensitizes cells to lymphokine-activated killer cell activity in MDA-MB-231 human breast cancer cells; induces rapid and sustained phosphorylation of ERK, p38 and JNK, also hyperactivates MKK4/SEK1; causes selective cancer cell cytotoxicity in part through non-redox-mediated activation of MAPK signaling. |
| Name | BCI-215 |
|---|
| Description | BCI-215 (BCI215) is a potent, tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor; restores defective MAPK activity caused by overexpression of DUSP1 and DUSP6 in mammalian cells; inhibits cell motility, causes apoptosis but not primary necrosis, and sensitizes cells to lymphokine-activated killer cell activity in MDA-MB-231 human breast cancer cells; induces rapid and sustained phosphorylation of ERK, p38 and JNK, also hyperactivates MKK4/SEK1; causes selective cancer cell cytotoxicity in part through non-redox-mediated activation of MAPK signaling. |
|---|---|
| References | References 1. Kaltenmeier CT, et al. J Pharmacol Exp Ther. 2017 Apr;361(1):39-50. View Related Products by Target Protein Phosphatase/PTP |
| Molecular Formula | C22H22BrNO |
|---|---|
| Molecular Weight | 396.328 |